AGM 2020 Presentation

November 18, 2020August 16, 2022 Alterity Therapeutics

2020

Post navigation

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2020 Presentation

Related Posts

Parkinson’s UK Awards £150,000 to Study Prana’s PBT434

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy